Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Niyazi, Maximilian ^a   Flieger, Maya ^a   Ganswindt, Ute ^a   Combs, Stephanie E ^b,c   Belka, Claus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bevacizumab; Glioblastoma; Glioma; Heidelberg score; Prognostic; Radiotherapy; Re irradiation

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HEIDELBERG SCORE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOENCEPHALOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION NECROSIS; RADIATION RESPONSE; RE IRRADIATION; RETREATMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT PLANNING; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; WORLD HEALTH ORGANIZATION; ADOLESCENT; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84903991279     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-128     Document Type: Article

References (30)

1. Niyazi M, Schnell O, Suchorska B, Schwarz SB, Ganswindt U, Geisler J, Bartenstein P, Kreth FW, Tonn JC, Eigenbrod S, Belka C, la Fougère C. FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiother Oncol 2012, 104(1):78-82. 10.1016/j.radonc.2012.04.022, 22673727.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5):459-466. 10.1016/S1470-2045(09)70025-7, 19269895.
3. Henke G, Paulsen F, Steinbach JP, Ganswindt U, Isijanov H, Kortmann RD, Bamberg M, Belka C. Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 2009, 185(2):113-119. 10.1007/s00066-009-1969-9, 19240998.
4. Vordermark D, Kolbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 2005, 5:55. 10.1186/1471-2407-5-55, 1156875, 15924621.
5. Niyazi M, Siefert A, Schwarz SB, Ganswindt U, Kreth FW, Tonn JC, Belka C. Therapeutic options for recurrent malignant glioma. Radiother Oncol 2010, 98(1):1-14.
6. Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 2010, 28(24):3838-3843. 10.1200/JCO.2010.30.0582, 2940401, 20644085.
7. Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol 2013, 52(1):147-152. 10.3109/0284186X.2012.692882, 22686472.
8. Jenab-Wolcott J, Giantonio BJ. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther 2009, 9(4):507-517. 10.1517/14712590902817817, 19344286.
9. Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011, 6:2. 10.1186/1748-717X-6-2, 3025871, 21214925.
10. Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Friedman AH, Friedman H, Reardon DA. A phase II study of bevacizumab plus etoposide among recurrent malignant glioma patients. Neuro-Oncology 2009, 11(5):633.
11. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2011, 118(5):1302-1312.
12. Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol 2011, 103(2):371-379. 10.1007/s11060-010-0403-6, 3102515, 20853132.
13. Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 2012, 107(1):155-164. 10.1007/s11060-011-0722-2, 3616617, 21986722.
14. Lorgis V, Maura G, Coppa G, Hassani K, Taillandier L, Chauffert B, Apetoh L, Ladoire S, Ghiringhelli F. Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol 2012, 107(2):351-358. 10.1007/s11060-011-0748-5, 22076449.
15. Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8(8):610-622.
16. Kil WJ, Tofilon PJ, Camphausen K. Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol 2012, 7:25. 10.1186/1748-717X-7-25, 3307492, 22356893.
17. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009, 75(1):156-163. 10.1016/j.ijrobp.2008.10.043, 3659401, 19167838.
18. Niyazi M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, Geisler J, la Fougere C, Ertl L, Linn J, Siefert A, Belka C. Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 2012, 82(1):67-76. 10.1016/j.ijrobp.2010.09.002, 21030162.
19. Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougere C, Ertl L, Linn J, Herrlinger U, Belka C, Niyazi M. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 2014, 117(2):337-345. Epub 2014 Feb 7, 10.1007/s11060-014-1394-5, 24504501.
20. Gallego Perez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, Gonzalez-Aguilar A, Houillier C, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 2012, 14(5):667-673. 10.1093/neuonc/nos070, 3337315, 22492961.
21. Combs SE, Bischof M, Welzel T, Hof H, Oertel S, Debus J, Schulz-Ertner D. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 2008, 89(2):205-210. 10.1007/s11060-008-9607-4, 18461281.
22. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 2009, 14(11):1131-1138. 10.1634/theoncologist.2009-0121, 19897538.
23. Hundsberger T, Brugge D, Putora PM, Weder P, Weber J, Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol 2013, 112(1):133-139. 10.1007/s11060-013-1044-3, 23314822.
24. Combs SE, Gutwein S, Thilmann C, Huber P, Debus J, Schulz-Ertner D. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol 2005, 74(2):167-171. 10.1007/s11060-004-2463-y, 16193388.
25. de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008, 14(5):279-285. 10.1097/PPO.0b013e3181867bd6, 18836331.
26. Niyazi M, Karin I, Sohn M, Nachbichler SB, Lang P, Belka C, Ganswindt U. Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma. Radiat Oncol 2013, 8:287. 10.1186/1748-717X-8-287, 4029146, 24330746.
27. Scholtyssek F, Zwiener I, Schlamann A, Seidel C, Meixensberger J, Bauer M, Hoffmann KT, Combs SE, von Bueren AO, Kortmann RD, Müller K. Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort. Radiat Oncol 2013, 8(1):161. 10.1186/1748-717X-8-161, 3707836, 23822643.
28. Niyazi M, Jansen N, Ganswindt U, Schwarz SB, Geisler J, Schnell O, Busing K, Eigenbrod S, la Fougere C, Belka C. Re-irradiation in recurrent malignant glioma: prognostic value of [(18)F]FET-PET. J Neurooncol 2012, 110(3):389-395. 10.1007/s11060-012-0980-7, 23054562.
29. Niyazi M, Zehentmayr F, Niemoller OM, Eigenbrod S, Kretzschmar H, Schulze-Osthoff K, Tonn JC, Atkinson M, Mortl S, Belka C. MiRNA expression patterns predict survival in glioblastoma. Radiat Oncol 2011, 6:153. 10.1186/1748-717X-6-153, 3235977, 22074483.
30. Combs SE, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J, Hartmann C. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?. Radiat Oncol 2011, 6:115. 10.1186/1748-717X-6-115, 3199258, 21910919.